Combined chemotherapy (cisplatin, cyclophosphamide, lomustine and vincristine) and multifractionation radiotherapy in inoperable nonmetastatic squamous cell lung cancer
Jazyk angličtina Země Slovensko Médium print
Typ dokumentu srovnávací studie, časopisecké články
PubMed
1528305
Knihovny.cz E-zdroje
- MeSH
- celková dávka radioterapie MeSH
- cisplatina aplikace a dávkování MeSH
- cyklofosfamid aplikace a dávkování MeSH
- kombinovaná terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lomustin aplikace a dávkování MeSH
- metastázy nádorů MeSH
- nádory plic farmakoterapie radioterapie terapie MeSH
- protokoly antitumorózní kombinované chemoterapie škodlivé účinky terapeutické užití MeSH
- spinocelulární karcinom farmakoterapie radioterapie terapie MeSH
- staging nádorů MeSH
- vinkristin aplikace a dávkování MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
- Názvy látek
- cisplatina MeSH
- cyklofosfamid MeSH
- lomustin MeSH
- vinkristin MeSH
A modified protocol was used in the treatment of inoperable nonmetastatic squamous cell lung cancer which consisted of three courses of induction chemotherapy with cisplatin, cyclophosphamide, lomustine and vincristine. Radiotherapy was delivered in multifractionated regime, daily two fractions of 1.5 Gy, 4 hours apart up to the total dose of 51 Gy. During 1985-1989, 77 patients were entered into the study. Twenty-six patients did not complete treatment, but were evaluated for the response rate and in survival analysis. There were 29 patients with Stage I and II, and 48 patients with Stage III lung cancer. After combined treatment CR was 15%, PR 39% and RR 54%. One- to four-year overall survival of 48 evaluable patients with Stage III were: 58%, 30%, 17% and 7%, respectively. The overall survival of the whole treatment group was significantly better than the survival of historical control group of 65 patients treated by radiotherapy only.
